A2A Pharmaceuticals, Inc.
Known title: 10% OwnerCIK: 0001859061
A2A Pharmaceuticals, Inc.'s purchase track record
A2A Pharmaceuticals, Inc. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2022 | BMEA | $426K | -40.8% | -22.3% | -3.9% |
| 9/17/2021 | BMEA | $380K | -34.2% | -48.8% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BMEA | ▼ Sell | Open Market | 50,000 | $1.7M | 6/1/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 75,000 | $2.5M | 5/31/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 25,000 | $846K | 5/12/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 150,000 | $5.2M | 5/9/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 100,000 | $3.4M | 5/8/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 200,000 | $5.8M | 4/20/2023 | View on chart |
| BMEA | ▼ Sell | Open Market | 200,000 | $6.3M | 3/31/2023 | View on chart |
| BMEA | ▲ Buy | Open Market | 30,684 | $426K | 8/16/2022 | View on chart |
| BMEA | ▼ Sell | Open Market | 34,658 | $389K | 7/21/2022 | View on chart |
| BMEA | ▼ Sell | Open Market | 34,658 | $408K | 6/24/2022 | View on chart |
| BMEA | ▲ Buy | Open Market | 34,658 | $380K | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Biomea Fusion Cancels Equity Offering, Shares Drop 19%
Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.
Biomea Fusion Cancels Equity Offering, Shares Drop 19%. Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.